Enanta Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
Get Alerts ENTA Hot Sheet
Join SI Premium – FREE
Presentation to be Webcast on June 23 at 10:30 a.m. ET
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present a corporate overview followed by a question and answer session with investors on June 23, 2015 at 10:30 a.m. ET during the JMP Securities Life Sciences Conference.
A live webcast and replay of the session can be accessed by visiting the “Calendar of Events” section on the “Investors” page of Enanta’s website at www.enanta.com. The replay webcast will be available following the presentation and will be archived for approximately 30 days.
About EnantaEnanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with AbbVie), NS5A, and nucleotide polymerase – as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Enanta’s lead protease inhibitor, paritaprevir, is part of AbbVie’s recently approved HCV treatment regimens. In addition, Enanta has a preclinical program in non-alcoholic steatohepatitis, or NASH, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150616005157/en/
Investor Contact
Enanta Pharmaceuticals, Inc.
Carol
Miceli, 617-607-0710
[email protected]
Source: Enanta Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The 48th WorldSkills Competition to Be Held in Shanghai, China
- Nexbie 3D Printed Sneakers Review: Are They Worth Buying?
- Hyundai Motor Group Accelerates Autonomous Driving Innovation with AI-Powered Data Flywheel
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share